Replication Data for: Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing

Immunotherapies are beneficial for a considerable proportion of cancer patients, but ineffective in others. In vitro modelling of the complex interactions between cancer cells and their microenvironment could provide a path to understanding immune therapy sensitivity and resistance. Here we develop...

Descripción completa

Detalles Bibliográficos
Autores: Perucca, Alice, Gomez-Llonin, Andrea, Mañé Benach, Oriol, Hallopeau, Clément, Rivas, Elisa Isabel, Linares, Jenniffer, Garrido, Marta, Sallent Aragay, Anna, Golde, Tom, Colombelli, Julien, Dalaka, Eleni, Linacero, Judith, Cazorla, Marina, Galan, Teresa, Pastor Viel, Jordi, Badenas, Xavier, Recort-Bascuas, Alba, Comerma Blesa, Laura, fernandez nogueira, patricia, Rovira, Ana, Roca-Cusachs, Pere, Albanell, Joan, Trepat, Xavier, Calon, Alexandre, Labernadie, Anna
Tipo de recurso: conjunto de datos
Fecha de publicación:2025
País:España
Institución:Consorci de Serveis Universitaris de Catalunya (CSUC)
Repositorio:CORA.Repositori de Dades de Recerca
OAI Identifier:oai:dnet:cora.rdr____::f30bfb3f8385b6a40997581607292c8c
Acceso en línea:https://doi.org/10.34810/DATA1891
Access Level:acceso abierto
Palabra clave:Medicine, Health and Life Sciences
Fibroblasts
Cells/immunology
Tumor Microenvironment
Microtechnology
Cancer biology
Immunotherapy
Descripción
Sumario:Immunotherapies are beneficial for a considerable proportion of cancer patients, but ineffective in others. In vitro modelling of the complex interactions between cancer cells and their microenvironment could provide a path to understanding immune therapy sensitivity and resistance. Here we develop MIRO, a fully humanised in vitro platform to model the spatial organisation of the tumour/stroma interface and its interaction with immune cells. We find that stromal barriers are associated with immune exclusion and protect cancer cells from antibody-dependent cellular cytotoxicity, elicited by targeted therapy. We demonstrate that IL2-driven immunomodulation increases immune cell velocity and spreading to overcome stromal immunosuppression and restores anti-cancer response in refractory tumours. Collectively, our study underscores the translational value of MIRO as a powerful tool for exploring how the spatial organisation of the tumour microenvironment shapes the immune landscape and influences the responses to immunomodulating therapies.

Similares en LA Referencia